CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Routine care for COVID-19 patientsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug954 favipiravir tablets+chloroquine phosphatetablets tablets Wiki 1.00
drug306 Favipiravir tablets Wiki 1.00
drug1005 plasma therapy using convalescent plasma with antibody against SARS-CoV-2 Wiki 1.00
drug616 Placebo Wiki 0.10

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.08
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia: a Prospective Randomized Trial

Plasma therapy using convalescent plasma has been shown to be effective in severe acute respiratory syndrome (1), Ebola virus infection (2) and in H1N1 influenza (3). More recently there has been a report of the use of convalescent plasma in the treatment of 5 ventilated COVID-19 patients with the suggestion of expedited recovery as the patients improved 1 week after the transfusion (4). However, this was not a clinical trial and the patients were on other antiviral medication.; therefore, there is a need to undertake such a trial to see if deploying plasma with SARS-CoV-2 neutralizing antibody has utility in managing patients infected with COVID-19 in respiratory distress. The objective of this pilot study is to compare plasma therapy using convalescent plasma with antibody against SARS-CoV-2 to usual supportive therapy in COVID-19 patients with pneumonia and hypoxia, and to determine if the clinical course is improved. The difference between groups will allow an effect size to be determined for a definitive clinical trial.

NCT04356534 SARS-CoV 2 COVID-19 Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2 Other: Routine care for COVID-19 patients

Primary Outcomes

Description: Could the plasma therapy avoid or delay the need for invasive ventilation

Measure: Requirement for invasive ventilation

Time: 10 day or until discharge

Secondary Outcomes

Description: Through the use of CT values

Measure: Time to viral clearance

Time: 10 day or until discharge

Description: Chest Xray

Measure: Radiological Improvement

Time: 10 day or until discharge

Description: As a measure of a reduction in inflammation

Measure: Reduction in white cell count

Time: 10 day or until discharge

Description: A reduction in C reactive protein as a measure of a reduction in inflammation

Measure: C reactive protein measurement

Time: 10 day or until discharge

Description: A reduction in lactate dehydrogenase as a measure of an improvement in the severity of the disease process

Measure: lactate dehydrogenase measurement

Time: 10 day or until discharge

Description: A reduction in procalcitonin as a measure of an improvement in the severity of the disease process

Measure: Procalcitonin measurement

Time: 10 day or until discharge

Description: A reduction in D Dimer as a measure of an improvement in the severity of the disease process

Measure: D Dimer measurement

Time: 10 day or until discharge

Description: A reduction in Ferritin as a measure of an improvement in the severity of the disease process

Measure: Ferritin measurement

Time: 10 day or until discharge

Description: A reduction in troponin T as a measure of an improvement in the severity of the disease process

Measure: Troponin T measurement

Time: 10 day or until discharge

Description: A reduction in brain naturetic peptide as a measure of an improvement in the severity of the disease process

Measure: Brain naturetic peptide measurement

Time: 10 day or until discharge

Description: Mortality rate due to COVID-19

Measure: Mortality rate

Time: Mortality rate at 28 days

No related HPO nodes (Using clinical trials)